LifeMD’s (LFMD) “Buy” Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of LifeMD (NASDAQ:LFMD) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Several other research firms have also recently issued reports on LFMD. B. Riley Financial lowered their target price on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a report on Friday, December 19th. KeyCorp lowered their price objective on shares of LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 19th. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Finally, HC Wainwright cut their target price on shares of LifeMD from $13.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, November 19th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.86.

LifeMD Trading Down 3.2%

LifeMD stock opened at $3.93 on Tuesday. The firm has a market cap of $189.19 million, a price-to-earnings ratio of 15.12 and a beta of 1.92. The stock has a fifty day simple moving average of $3.32 and a two-hundred day simple moving average of $4.56. LifeMD has a 12 month low of $2.56 and a 12 month high of $15.84.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%. The business had revenue of $46.87 million for the quarter, compared to the consensus estimate of $48.57 million. On average, equities research analysts forecast that LifeMD will post -0.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of LifeMD by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock valued at $270,000 after acquiring an additional 2,235 shares during the period. Tower Research Capital LLC TRC raised its holdings in LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares during the period. SG Americas Securities LLC raised its holdings in LifeMD by 13.8% in the 4th quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock worth $86,000 after purchasing an additional 3,061 shares during the period. Invesco Ltd. grew its holdings in LifeMD by 18.8% during the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock valued at $83,000 after purchasing an additional 3,870 shares during the period. Finally, Rhumbline Advisers increased its position in LifeMD by 8.7% in the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after buying an additional 4,281 shares in the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.